Regression of a distal bile duct carcinoma after treatment with octreotide for 6 months

Digestion

Volumn 58, Issue 4, 1997, Pages 407-409

  Sulkowski, U ^a   Dime, P ^a   Haus, V ^b   Collins, W ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Sandoz Pharma AG   (Germany)

^c Sandoz Pharma Ltd   (Switzerland)

Author keywords

Bile duct carcinoma; Down staging; Octreotide; Pancreatic carcinoma; Somatostatin receptor

Indexed keywords

HYPOTHALAMUS RELEASE INHIBITING FACTOR; OCTREOTIDE; SOMATOSTATIN RECEPTOR;

AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER INVASION; CANCER REGRESSION; CASE REPORT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; HUMAN; LAPAROTOMY; MALE; MESENTERY BLOOD VESSEL; OBSTRUCTIVE JAUNDICE; PANCREAS CARCINOMA; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BILE DUCT NEOPLASMS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLESTASIS; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; MALE; OCTREOTIDE; PANCREATIC NEOPLASMS; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0030801880     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201475     Document Type: Article

References (4)

1. Büchler M, Sulkowski U, Pederaoli P, Arnold R, Dinse P, Mictlowski W, Israel R: A phase-11 study of octreotide (SMS) in advanced pancreatic cancer (abstract). Proc ASCO 1994; 13;214.
2. Alden ME, Mohiuddin M: The impact of radiation dose in combined external beam und Ir-192 braehytherapy for bile duct cancer. Int J Radial Oncol Biol Pliys 1994:28:945-951.
3. Ebert M, Friess H, Reger HG, Büchler M: Role of octreotide in the treatment of pancreatic cancer. Digestion 1994,55(suppl 1):48-51
4. Tan CK, Podilu PV, Taylor JE, Nagomev DM, Wiseman CJA, Gores GJ, Lirusso NF: Human cholangiocarcinomos express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology 1995:108: 1908-1916.